New clinical applications for the alkaloid berberine have come to light in recent years. Applications related to adenosine monophosphate-activated protein kinase (AMPK) activation and berberine’s possible therapeutic use in metabolic syndrome, type 2 diabetes, and dyslipdemia are reviewed in this article. Potential applications related to cancer are not discussed here but are reserved for a second review.
In recent years, the botanical extract berberine has been pushed from relative obscurity to front and center on our supplement shelves due to newly published research. Over a third of the approximately 2,800 studies on berberine listed on PubMed were published in the last 5 years. These studies reveal that berberine may have clinical applications in a range of conditions.
The chemical berberine is found in a handful of plants widely used in botanical medical practice including Goldenseal (Hydrastis canadensis), Oregon grape (Berberis aquifolium), Barberry (Berberis vulgaris), and Chinese Goldthread (Coptis chinensis). Two other berberine-containing plants that are familiar to practitioners of Chinese medicine are Phellodendron chinense and Phellodendron amurense.
Berberine is yellow in color, and plants containing berberine often have been used as a dye, particularly for coloring wool. Chemically, berberine is classified as an isoquinoline alkaloid.
For the past 15 years, our understanding of berberine has been based on an article written by Tim Birdsall and Greg Kelly that was published in Alternative Medicine Review in 1997.1 These sagacious colleagues focused on the relatively short list of actions of berberine that were known at the time:
- Antimicrobial action against bacteria, fungi, protozoa, viruses, helminthes, and Chlamydia
- Antagonism against the effects of cholera and E coli heat-stable enterotoxin
- Inhibition of intestinal ion secretion and of smooth muscle contraction
- Reduction of inflammation
- Stimulation of bile secretion and bilirubin discharge
At the time the article was written, berberine was assumed to be useful for the treatment of infectious gastritis, and for many years berberine was placed on the pharmacy shelf where supplements for “GI complaints” were found. These days, berberine may deserve a shelf of its own.
There are 3 general conditions for which we should consider berberine: metabolic syndrome, inflammation, and cancer. This review will cover the first of these 3 conditions, metabolic syndrome.
The fundamental mechanism of action underlying berberine’s impact on human health is probably its action on the adenosine monophosphate-activated protein kinase or AMP-activated protein kinase (AMPK). To understand what berberine does, one must first understand AMPK. This enzyme acts as the central energy regulatory control switch regulating how energy is produced and used in the body. AMPK induces a cascade of events within cells that are all involved in maintaining energy homeostasis. The AMPK system senses and responds to changes in energy metabolism both on the cellular and the whole-body level. It is via AMPK that low energy status switches cellular metabolism from ATP-consuming anabolic pathways to ATP-producing catabolic pathways.
AMPK regulates an array of biological activities that normalize lipid, glucose, and energy imbalances. Metabolic syndrome (MetS) occurs when these AMPK-regulated pathways are turned off, triggering a syndrome that includes hyperglycemia, diabetes, lipid abnormalities, and energy imbalances.2
AMPK has been proposed as a target for drug monotherapy treatment of metabolic syndrome. Current MetS treatment typically employs 3 to 5 different medications to manage the different comorbidities such as hyperglycemia, hypertension, hyperlipidemia, and inflammation.3 In theory, a single medication that activates AMPK could replace all of the medications used to treat these various aspects of MetS. Rather than treating symptoms, controlling the AMPK switch may control the entire gamut of metabolic syndrome symptoms.4
AMPK helps coordinate the response to these stressors, shifting energy toward cellular repair, maintenance, or a return to homeostasis and improved likelihood of survival. The hormones leptin and adiponectin activate AMPK. In other words, activating AMPK can produce the same benefits as exercise, dieting, and weight loss—the lifestyle modifications considered beneficial for a range of maladies.
While AMPK is activated by energy depletion, it is inhibited by energy excess.
High glucose and glycogen levels inhibit AMPK. This inhibition leads to many of the long-term consequences of diabetes. Exercise and caloric restriction activate AMPK, and this explains their benefit in treating diabetes. High fat intake also inhibits AMPK.
One way to appreciate berberine’s potential is to think of it as having the same effect on a patient as increasing exercise while at the same time restricting calorie intake. Think of the effects of AMPK suppression as similar to those of eating a high-calorie diet while leading a very sedentary lifestyle.
Only a few chemicals are known to activate AMPK. Berberine is one of them. Reports that berberine activates AMPK were first published in 2006.5 Resveratrol, salicylate, and metformin also activate this chemical pathway.6,7
AMPK activation was cited early on as an explanation of berberine’s ability to improve glucose control in diabetic animals. Berberine increases glucose uptake by muscle fibers independent of insulin levels.8 Berberine triggers AMPK activation and increases glycolysis, leading to decreased insulin resistance and decreased oxygen respiration.9 The same mechanism leads to a reduction in gluconeogenesis in the liver.10 AMPK activation also explains why berberine has an antiatherosclerotic effect in mice.11 The same mechanism is reported to underlie berberine’s antiobesity effects and favorable influence on weight loss.12
Caloric restriction and increased exercise also affect the likelihood of one contracting cancer.13 Thus it is understandable that berberine-induced AMPK activation is cited for some of its anticancer effects—for example, berberine’s ability to inhibit metastasis of melanoma cells.14 Berberine’s ability to blunt and suppress proinflammatory responses is also mediated through AMPK activation.15 There is such a significant amount of published and ongoing research into berberine’s anticancer potential that I have chosen not to cover it in this review but instead to review it specifically at a later time.
One way to understand berberine’s action in diabetes is to consider the actions of metformin, a common pharmaceutical drug that is also an AMPK activator.16 Metformin activates AMPK to a similar degree as berberine, and as a result, they affect metabolism similarly. So it should be no surprise that, like metformin, berberine appears useful for treating type-2 diabetes.
Berberine has been used successfully to treat experimental diabetes in test animals.17,18 It has also been used to treat type-2 diabetes in human trials.19–22
There are 3 general conditions for which we should consider berberine: metabolic syndrome, inflammation, and cancer.
Wang reported in 2009 that berberine (100 mg/kg) restored the vascular endothelial function by increasing nitric oxide levels in rats in which diabetes had been induced by a combination of high-fat diets and treatment with streptozotocin.23 Wang et al reported similar benefits in a similar rat model in 2011. In this case, the diabetic rats were treated with ascending doses of berberine: 0 (control), 50, 100, and 150 mg/kg/d of berberine for 6 weeks. The hypoglycemic effects of berberine were evidenced in the fasting blood glucose levels and insulin-sensitizing effects.24
In 2008, Yin reported the results of 2 human trials in the journal Metabolism on patients newly diagnosed with type-2 diabetes who were randomly treated to take either berberine or metformin (500 mg 3 times a day) in a 3-month trial. The hypoglycemic effect of berberine was similar to that of metformin. In the first study (n=36), the hypoglycemic effect of berberine was similar to metformin with a 2% decrease in A1c (P<0.01) and fasting blood glucose (-8.7 mmo/L, P<.01). In the second study (n=48), patients with poorly controlled type-2 diabetes took berberine for 3 months. Hemoglobin A1c decreased from 8.1% to 7.3% (P<.001).25
A recent meta-analysis by Dong et al combined data from 14 randomized trials involving 1,068 participants. Treatment with both berberine and lifestyle modification showed significant hypoglycemic and antidyslipidemic benefits. The effects did not differ from those obtained by the standard hypoglycemic drugs metformin, glipizide, or rosiglitazone.26
Berberine has been studied and shown to be effective in treating other conditions that respond to metformin.
In January 2012, the European Journal of Endocrinology published results of a clinical trial that found berberine compared favorably with metformin when used to treat women (n=89) with polycystic ovary syndrome (PCOS).27 A year earlier, an article in Fertility and Sterility reported that berberine reduces insulin resistance in ovarian theca cells and decreased their excessive testosterone production.28
Berberine, like metformin, appears to be useful for treating metabolic syndrome. Not only does it reduce insulin resistance but it also normalizes the lipid profiles characteristic of the condition.29
Berberine, like metformin, can help reduce the side effect of weight gain triggered by antipsychotic medications.30, 31
Researchers have become intrigued by the potential benefit metformin has in treating cancer. It is possible that berberine will have a parallel action.
Berberine increases expression of insulin receptors and so reduces insulin resistance.32,33 A 2009 study in China suggested that a synergistic action occurs when berberine is combined with metformin or 2,4-thiazolidinedione (THZ) (a peroxisome proliferator-activated receptor [PPAR] activator used to treat diabetes) and might allow a reduction in the amount of these drugs required for treatment and so reduce the risk of toxicity.34
If one thinks of AMPK activation as “something that reverses metabolic syndrome,” then several other aspects of metabolic syndrome and potential actions for berberine come to mind. Aside from hyperglycemia, there are 3 other hallmarks of metabolic syndrome: dyslipidemia, fatty liver, and inflammation.
Berberine has a positive impact on all 3.
A December 2004 article described berberine as “a novel cholesterol-lowering drug” that worked through a “unique mechanism distinct from statins.” The authors had given berberine to 32 hypercholesterolemic patients for 3 months. The treatment reduced serum cholesterol by 29%, triglycerides by 35%, and LDL-cholesterol by 25%.35
A 2009 study reported that in rats, AMPK activation triggered by berberine prevented the development of fatty liver.36 This was followed in 2011 by a randomized controlled trial of 60 humans with fatty liver disease. The tracking of numerous biomarkers showed that 3 months of “berberine can obviously improve the conditions.” Liver ultrasounds of the study participants showed a 70% improvement. Total cholesterol and triglycerides also decreased significantly in this trial. These patients took 0.5 g of berberine twice per day.37
According to a randomized controlled trial conducted in 2008 with diabetic rats in which dyslipidemia had been induced with a combination of streptozotocin and a high-fat diet, “Berberine reduced diabetic rats’ body weight, liver weight and liver to body weight ratio. Berberine restored the increased blood glucose, hemoglobin A1c, total cholesterol, triglyceride, low density lipoprotein-cholesterol, apolipoprotein B and the decreased high density lipoprotein-cholesterol, apolipoprotein AI levels in diabetic rats to near the control ones. Berberine alleviated the pathological progression of liver and reverted the increased hepatic glycogen and triglyceride to near the control levels.”38
A 2010 human clinical trial analyzed changes in serum metabolites, particularly free fatty acid levels, in 60 patients with type-2 diabetes who had taken berberine. The berberine group had significantly lower levels of free fatty acids, chemicals that are toxic to the pancreas and linked with insulin resistance.39,40
Berberine’s lipid-lowering mechanism of action is different from that found in the statin drugs.41 Combining berberine with statin drugs has a synergistic effect and is more effective than using either alone. In 2008, a Chinese researcher reported in the journal Metabolism results of a study that combined berberine with simvastatin. The researchers began by treating hyperlipidemic rats with a combination of both agents together or as monotherapies; the combination of both agents reduced cholesterol by 46% while simvastatin alone reduced cholesterol by 28% and berberine alone by 27%. Combination therapy was then tried on 63 hypercholesterolemic patients. The combined therapy lowered LDL cholesterol 32% more than either monotherapy. Similar benefits were seen with total cholesterol and triglycerides.42
Similar synergistic action was seen in an experiment using hyperlipidemic hamsters and treating them with a combination of berberine and plant stanols.43
While improving lipids may improve cardiovascular disease (CVD) risk, berberine has other beneficial actions that lower CVD risk. It improves arterial endothelial function and suppresses proinflammatory cytokines, actions that should improve heart health.44–48
Adding berberine to cultures of human macrophage–derived foam cells, which had been induced by oxidized LDL, significantly inhibits the effect of oxidized LDL in a dose- and time-dependent manner and inhibits the expression of its lectin-like receptor (LOX-1) actions suggesting that berberine could be useful in treating atherosclerotic diseases.49
A July 2003 study published in the American Journal of Cardiology examined the use of berberine in congestive heart failure (CHF). The authors randomly divided 156 patients with CHF into 2 groups. All patients were treated with conventional therapy but 1 group of 79 patients was also given berberine at a dose of 1.2 to 2.0 grams per day. After 8 weeks of berberine treatment, “there was a significantly greater increase in left ventricular ejection fraction, exercise capacity, improvement of the dyspnea-fatigue index, and a decrease of frequency and complexity of VPCs [ventricular premature complexes] compared with the control group. There was a significant decrease in mortality in the berberine-treated patients during long-term follow-up (7 patients receiving treatment died vs 13 on placebo, P<.02).” Proarrhythmia was not observed, and there were no apparent side effects.”50
A second chemical pathway of interest when considering therapeutic applications of berberine to diabetes is the aldose reductase pathway. Aldose reductase is the rate-limiting enzyme in the polyol pathway. It reduces glucose to sorbitol using NADPH (nicotinamide adenine dinucleotide phosphate) as a cofactor. Sorbitol is then metabolized to fructose by sorbitol dehydrogenase. In healthy people, only a small amount of glucose (less than 3%) moves through this pathway. However, in the presence of high glucose levels, as much as 30% of total glucose will follow this path. In diabetics, this abnormal flow of glucose down the polyol pathway leads to the accumulation of large amounts of sorbitol, which in turn leads to both osmotic and oxidative stress in the tissues where sorbitol accumulates.51 Aldose reductase plays a significant role in much of the pathology caused by diabetes, including diabetic neuropathy, retinopathy, and nephropathy.52
Lee’s 2002 report in the Journal of Agriculture and Food Chemistry revealed that berberine is an aldose reductase inhibitor.53
In 2 separate articles published in 2008, Liu reported that berberine extracts protected or helped repair the kidneys of diabetic mice partly through aldose reductase inhibition.54,55 Berberine reduced oxidative stress in the kidneys.56
Aldose reductase plays a role in diabetic cataract formation, and inhibition helps prevent cataract formation.57
Because of these properties, berberine alkaloids “would clearly have beneficial uses in the development of therapeutic and preventive agents for diabetic complications and diabetes mellitus.”58
A number of other chemical pathways have been delineated that underlie berberine’s antidiabetic actions. Berberine inhibits dipeptidyl peptidase-4 (DPP IV) and human protein tyrosine phosphatase 1B (h-PTP 1B).59 It suppresses production of intestinal disaccharidases, reducing sugar digestion and absorption.60 It improves glucose metabolism by inducing glycolysis.61 It also increases glucose transporter-4 (GLUT-4) and glucagon-like peptide-1 (GLP-1) levels.62 The peptide GLP-a is more commonly known by the name incretin.63 Historically, incretin is the first hormone to have been identified. It is secreted by the small intestine after eating and triggers release of insulin. Exenatide (Byetta) and liraglutide (Victoza), both incretin mimetics, have been developed and are now prescribed to treat type-2 diabetes.64
Berberine was thought to be poorly absorbed across the gut wall. Pharmacokinetic researchers have certainly found low plasma concentrations—levels so low that “the remarkable variety of pharmacological effects exerted by Ber[berine] at blood concentrations below the effective dose required for activity in vitro has been regarded with considerable skepticism.”65
The pharmacokinetics of berberine are “obscure because plasma concentrations after p.o. administration are too low to detect using general analytic approaches such as HPLC.”66 As a result, it had been assumed that very little if any berberine is absorbed.
It now appears that the situation is more complex; berberine actually appears to be well absorbed. The confusion lies in the fact that it is quickly metabolized. Blood clearance is so fast and biotransformation in the liver so rapid that berberine disappears from the blood faster than it can be measured. Berberine metabolites may be responsible for berberine’s biological action.
Most berberine is metabolized in the liver through phase I demethylation and phase II glucuronidation, after which the metabolites are excreted with the bile.
Considerable interest has been directed toward creating nanoparticle delivery systems for berberine, the assumption being that therapeutic effects will increase with increased absorption. These delivery systems fall into 3 general types: solid lipid nanoparticles, nanoemulsions, and liposomes.67
Wang et al compared the blood sugar–lowering effect of a nanoemulsion made of phosphatidyl-choline micelles and berberine against intravenously administered and plain oral berberine in diabetic mice. Intravenous injection of a berberine solution lowered blood sugar by 22% while the oral nanoemulsion of berberine lowered blood sugar levels by 57%. The blood glucose–lowering effect of standard oral berberine did not reach statistical significance in this trial.68
Results like these are exciting; they suggest the potential for much stronger impact. Enhanced oral delivery systems that could increase the clinical effectiveness of berberine will likely be introduced in the coming years.
What Was Left Out?
This review has by and large ignored several major therapeutic applications for berberine. A second article will review berberine’s potential use in treating inflammatory conditions, cancer, depression, and neurodegenerative illnesses.
While the known clinical applications for berberine are diverse and becoming more so over time, there are a few generalizations we might make that will allow us to understand berberine’s potential. Berberine activates AMPK in a manner similar to how exercise stimulates increased strength and weight loss. Thus, any condition that would be favorably impacted by a patient losing weight and/or exercising more may be impacted favorably by oral berberine supplementation. It makes sense to consider using berberine in patients with insulin resistance, pre-diabetes, diabetes, metabolic syndrome, hypertension, heart disease, dyslipidemia, cancer, depression, and other neuropsychiatric diseases. We also can look at conditions improved by other AMPK-activating drugs, in particular metformin, to help make educated guesses of other possible applications that may soon be revealed.
1. Birdsall T, Kelly G. Berberine: therapeutic potential of an alkaloid found in several medicinal plants. Alt Med Rev. 1997;2(2):94-103. Available here.
2. Srivastava RA, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, Newton RS. AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res. 2012;53(12):2490-2514.
4. Hwang JT, Kwon DY, Yoon SH. AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols. N Biotechnol. 2009;26(1-2):17-22.
5. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55(8):2256-2264.
6. Skrobuk P, von Kraemer S, Semenova MM, Zitting A, Koistinen HA. Acute exposure to resveratrol inhibits AMPK activity in human skeletal muscle cells. Diabetologia. 2012;55(11):3051-3060.
7. Hardie DG, Ross FA, Hawley SA. AMP-activated protein kinase: a target for drugs both ancient and modern. Chem Biol. 2012;19(10):1222-1236.
8. Cheng Z, Pang T, Gu M, et al. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim Biophys Acta. 2006;1760(11):1682-1689.
9. Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2008;294(1):E148-156.
10. Xia X, Yan J, Shen Y, et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One. 2011;6(2):e16556.
11. Wang Q, Zhang M, Liang B, Shirwany N, Zhu Y, Zou MH. Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2. PLoS One. 2011;6(9):e25436.
12. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55(8):2256-2264.
13. Imayama I, Ulrich CM, Alfano CM, et al. Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res. 2012;72(9):2314-2326.
14. Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS, Lim JS. Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem Pharmacol. 2012;83(3):385-394.
15. Jeong HW, Hsu KC, Lee JW, et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab. 2009;296(4):E955-964.
16. Salt IP, Palmer TM. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. Expert Opin Investig Drugs. 2012;21(8):1155-1167.
17. Wang C, Li J, Lv X, et al. Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. Eur J Pharmacol. 2009;620(1-3):131-137.
18. Wang Y, Campbell T, Perry B, Beaurepaire C, Qin L. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats. Metabolism. 2011;60(2):298-305.
19. Gu Y, Zhang Y, Shi X, et al. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta. 2010;81(3):766-772.
20. Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010;59(2):285-292.
21. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559-2565.
22. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712-717.
23. Wang C, Li J, Lv X, et al. Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. Eur J Pharmacol. 2009;620(1-3):131-137.
24. Wang Y, Campbell T, Perry B, Beaurepaire C, Qin L. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats. Metabolism. 2011;60(2):298-305.
25. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712-717.
26. Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med. 2012;2012:591654.
27. Wei W, Zhao H, Wang A, et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012;166(1):99-105.
28. Zhao L, Li W, Han F, et al. Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro. Fertil Steril. 2011;95(1):461-463.
29. Kong WJ, Zhang H, Song DQ, et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism. 2009;58(1):109-119.
30. Adeneye AA, Agbaje EO, Olagunju JA. Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats. Indian J Exp Biol. 2011;49(5):332-338.
31. Hu Y, Kutscher E, Davies GE. Berberine inhibits SREBP-1-related clozapine and risperidone induced adipogenesis in 3T3-L1 cells. Phytother Res. 2010;24(12):1831-1838.
32. Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010;59(2):285-292.
33. Liu LZ, Cheung SC, Lan LL, et al. Berberine modulates insulin signaling transduction in insulin-resistant cells. Mol Cell Endocrinol. 2010;317(1-2):148-153.
34. Prabhakar PK, Doble M. Synergistic effect of phytochemicals in combination with hypoglycemic drugs on glucose uptake in myotubes. Phytomedicine. 2009;16(12):1119-1126.
35. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344-1351.
36. Kim WS, Lee YS, Cha SH, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab. 2009;296(4):E812-819.
37. Xie X, Meng X, Zhou X, Shu X, Kong H. [Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]. Zhongguo Zhong Yao Za Zhi. 2011;36(21):3032-3035.
38. Zhou JY, Zhou SW, Zhang KB, et al. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull. 2008;31(6):1169-1176.
39. Gu Y, Zhang Y, Shi X, et al. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta. 2010;81(3):766-772.
40. Capurso C, Capurso A. From excess adiposity to insulin resistance: The role of free fatty acids. Vascul Pharmacol. 2012;57(2-4):91-97.
41. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344-1351.
42. Kong WJ, Wei J, Zuo ZY, et al. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism. 2008;57(8):1029-1037.
43. Wang Y, Jia X, Ghanam K, Beaurepaire C, Zidichouski J, Miller L. Berberine and plant stanols synergistically inhibit cholesterol absorption in hamsters. Atherosclerosis. 2010;209(1):111-117.
44. Wang JM, Yang Z, Xu MG, et al. Berberine-induced decline in circulating CD31+/CD42- microparticles is associated with improvement of endothelial function in humans. Eur J Pharmacol. 2009;614(1-3):77-83.
45. Ko WH, Yao XQ, Lau CW, et al. Vasorelaxant and antiproliferative effects of berberine. Eur J Pharmacol. 2000;399(2-3):187-196.
46. Wang Q, Zhang M, Liang B, Shirwany N, Zhu Y, Zou MH. Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2. PLoS One. 2011;6(9):e25436.
47. Xu MG, Wang JM, Chen L, Wang Y, Yang Z, Tao J. Berberine-induced mobilization of circulating endothelial progenitor cells improves human small artery elasticity. J Hum Hypertens. 2008;22(6):389-393.
48. Lee S, Lim HJ, Park HY, Lee KS, Park JH, Jang Y. Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model. Atherosclerosis. 2006;186(1):29-37.
49. Guan S, Wang B, Li W, Guan J, Fang X. Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL. Am J Chin Med. 2010;38(6):1161-1169.
50. Zeng XH, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2003;92(2):173-176.
51. Tang WH, Martin KA, Hwa J. Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol. 2012;3:87.
52. Saraswat M, Muthenna P, Suryanarayana P, Petrash JM, Reddy GB. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications. Asia Pac J Clin Nutr. 2008;17(4):558-565.
53. Lee HS. Rat lens aldose reductase inhibitory activities of Coptis japonica root-derived isoquinoline alkaloids. J Agric Food Chem. 2002;50(24):7013-7016.
54. Liu W, Liu P, Tao S, et al. Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. Arch Biochem Biophys. 2008;475(2):128-134.
55. Liu WH, Hei ZQ, Nie H, et al. Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. Chin Med J (Engl). 2008;121(8):706-712.
57. Kawakubo K, Mori A, Sakamoto K, Nakahara T, Ishii K. GP-1447, an inhibitor of aldose reductase, prevents the progression of diabetic cataract in rats. Biol Pharm Bull. 2012;35(6):866-872.
58. Jung HA, Yoon NY, Bae HJ, Min BS, Choi JS. Inhibitory activities of the alkaloids from Coptidis Rhizoma against aldose reductase. Arch Pharm Res. 2008;31(11):1405-1412.
59. Al-masri IM, Mohammad MK, Tahaa MO. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J Enzyme Inhib Med Chem. 2009;24(5):1061-1066.
60. Liu L, Yu YL, Yang JS, et al. Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol. 2010;381(4):371-381.
61. Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2008;294(1):E148-156.
62. Cicero AF, Tartagni E. Antidiabetic properties of berberine: from cellular pharmacology to clinical effects. Hosp Pract (Minneap). 2012;40(2):56-63.
63. Lu SS, Yu YL, Zhu HJ, et al. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. J Endocrinol. 2009;200(2):159-165.
64. Murphy CE. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2012;46(6):812-821.
65. Zuo F, Nakamura N, Akao T, Hattori M. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos. 2006;34(12):2064-2072.
67. Tan W, Li Y, Chen M, Wang Y. Berberine hydrochloride: anticancer activity and nanoparticulate delivery system. Int J Nanomed. 2011:6;1773-1777.
68.Wang T, Wang N, Song H, et al. Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine. Eur J Pharm Sci. 2011;44(1-2):127-135.